Invion Limited

Invion Limited

IVIXF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.65M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Invion LimitedInvion Limited-0.5--271%-0.3
$-0.02

Current Fair Value

141.5% downside

Overvalued by 141.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.65 Million
Enterprise Value$4.60 Million
Earnings per Share$-0.04
Beta0.4
Outstanding Shares99,085,914

Return

Return on Equity-271.45%ROE
Return on Assets-176.82%
Return on Invested Capital-272.08%

Valuation & Multiples

P/E Ratio-0.53P/E Ratio
PEG0.75PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue11.97
Enterprise Value to EBIT-0.32
Enterprise Value to Net Income-1
Total Debt to Enterprise0.34
Debt to Equity0.29Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Invion Limited

4 employees
CEO: Thian Chew

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions ...